[Refractory acute promyelocytic leukemia with a complex karyotype]

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia.
• Standard induction and consolidation therapies, including all-trans retinoic acid and arsenic trioxide, are highly effective for APL.
• Relapsed APL often responds to further chemotherapy or autologous stem cell transplantation.

Observation:

• A 46-year-old woman with APL achieved initial remission but relapsed 6 months after maintenance therapy.
• Re-induction chemotherapy failed to achieve remission.
• Allogeneic bone marrow transplantation was performed but the patient experienced rapid disease progression and death post-transplant.

Findings:

• The patient's APL was refractory to multiple treatment regimens, including idarubicin+AraC and high-dose AraC.
• APL cells reappeared in peripheral blood 12 days post-transplantation, leading to rapid deterioration.
• This case highlights a highly refractory APL with a poor prognosis despite aggressive treatment.

Implications:

• This refractory APL case may represent a variant with a different underlying pathogenesis than typical APL.
• Further research into APL resistance mechanisms is warranted.
• Understanding unique APL subtypes is crucial for developing targeted therapies.